Obesity Could Be Pharma’s Biggest Blockbuster

As the popularity of drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro grow rapidly, patient testimonies have focused not only on the dramatic weight-loss effect but also on how quickly many seem to regain weight if they stop taking the injections. Investors can get excited by a product whose target market is so large (apparently more than 40 percent of American adults are obese) and the medicine must be taken indefinitely.